down arrow

Monopar Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US61023L1089
USD
79.47
3.53 (4.65%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

75.4779.90

52 Week

20.16105.00
Valuation
Technical
Day's Volume

CASH

155.09 k

Shareholding (Mar 2025)

FII

0.86%

Held by 12 FIIs

DII

97.37%

Held by 2 DIIs

Promoter

0.00%

How big is Monopar Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Monopar Therapeutics, Inc. has a market capitalization of 208.53 million, with net sales of 0.00 million and a net profit of -16.57 million over the latest four quarters. The company reported shareholder's funds of 55.04 million and total assets of 60.29 million as of Dec 24.

Market Cap: As of Jun 18, Monopar Therapeutics, Inc. has a market capitalization of 208.53 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Monopar Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -16.57 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 55.04 million and total assets of 60.29 million.

Read More

What does Monopar Therapeutics, Inc. do?

22-Jun-2025

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing cancer therapeutics, with a market cap of approximately $208.53 million and a recent net profit of -$3 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

Overview:<BR>Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics for cancer patients, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 208.53 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -30.92% <BR>Price to Book: 3.89<BR><BR>Contact Details:<BR>Address: 1000 Skokie Blvd Ste 350, WILMETTE IL: 60091-1146 <BR>Tel: 1 847 3880349 <BR>Fax: 1 302 6555049 <BR>Website: https://www.monopartx.com/

Read More

Is Monopar Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Monopar Therapeutics, Inc. shows a bullish technical trend, supported by strong indicators like MACD and Bollinger Bands, despite some mixed signals from Dow Theory and OBV.

As of 11 September 2025, the technical trend for Monopar Therapeutics, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate bullish conditions for both periods. Daily moving averages are bullish, while the KST shows bullish signals on both weekly and monthly charts. However, the Dow Theory indicates a mildly bullish stance on both time frames, and the OBV is mildly bullish weekly but mildly bearish monthly. Overall, the bullish indicators outweigh the bearish ones. There is no available multi-period return data for comparison with the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 256 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.02

stock-summary
Return on Equity

-33.16%

stock-summary
Price to Book

4.90

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
119.47%
0%
119.47%
6 Months
147.49%
0%
147.49%
1 Year
242.99%
0%
242.99%
2 Years
4716.36%
0%
4716.36%
3 Years
2910.23%
0%
2910.23%
4 Years
318.26%
0%
318.26%
5 Years
228.05%
0%
228.05%

Monopar Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Monopar Therapeutics, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Monopar Therapeutics, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate bullish conditions for both periods. Daily moving averages are bullish, while the KST shows bullish signals on both weekly and monthly charts. However, the Dow Theory indicates a mildly bullish stance on both time frames, and the OBV is mildly bullish weekly but mildly bearish monthly. Overall, the bullish indicators outweigh the bearish ones. There is no available multi-period return data for comparison with the S&P 500....

Read More
Monopar Therapeutics Hits New 52-Week High at $68.18

Monopar Therapeutics Hits New 52-Week High at $68.18

Monopar Therapeutics, Inc. has achieved a new 52-week high of USD 68.18, significantly up from its low of USD 3.90. With a market capitalization of USD 256 million, the company operates in the Pharmaceuticals & Biotechnology sector, facing challenges reflected in its financial metrics.

Read More
Monopar Therapeutics Stock Soars to New 52-Week High of $58.94

Monopar Therapeutics Stock Soars to New 52-Week High of $58.94

Monopar Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. With a market capitalization of USD 256 million, the company operates at a loss and has a unique financial structure, highlighting its evolving position in the biotechnology sector.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-216.79%
EBIT to Interest (avg)
-10.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
48.13%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.23
EV to EBIT
-9.76
EV to EBITDA
-9.76
EV to Capital Employed
-172.38
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-30.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.77%)

Foreign Institutions

Held by 12 Foreign Institutions (0.86%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -47.06% vs 22.73% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.20",
          "val2": "-1.80",
          "chgp": "-77.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-1.70",
          "chgp": "-47.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -85.71% vs 20.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.20",
          "val2": "-8.80",
          "chgp": "-84.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.60",
          "val2": "-8.40",
          "chgp": "-85.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.20
-1.80
-77.78%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.50
-1.70
-47.06%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -47.06% vs 22.73% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-16.20
-8.80
-84.09%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.60
-8.40
-85.71%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -85.71% vs 20.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Monopar Therapeutics, Inc. stock-summary
stock-summary
Monopar Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Monopar Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for cancer patients. Its pipeline includes Validive, Camsirubicin and MNPR-101. Validive is a clonidine mucobuccal tablet (clonidine MBT). Validive is designed to be used prophylactically to reduce the incidence, delay the time to onset, and decrease the duration of severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. Its second product candidate, Camsirubicin, is a novel analog of doxorubicin. Camsirubicin is designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining anti-cancer activity. MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. It is developing MNPR-101 for the treatment of advanced cancers.
Company Coordinates stock-summary
Company Details
1000 Skokie Blvd Ste 350 , WILMETTE IL : 60091-1146
stock-summary
Tel: 1 847 3880349
stock-summary
https://www.monopartx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."